Why the study?
This study sought to evaluate outcomes of rivaroxaban monotherapy compared with combination therapy across body mass index categories in patients with atrial fibrillation and stable coronary artery disease.
Does rivaroxaban monotherapy improve efficacy and safety compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease across different BMI categories?
Does rivaroxaban monotherapy improve efficacy and safety compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease across different BMI categories?
Rivaroxaban monotherapy maintains consistent efficacy and safety benefits over combination therapy across different BMI categories in patients with atrial fibrillation and stable coronary artery disease.
Answers are grounded in this paper and cite their sources.
Supports monotherapy preference by BMI in AF with stable CAD; extends RCT evidence on consistent effects across weight categories.
Background: The AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial showed both noninferiority for efficacy and superiority for safety endpoints of rivaroxaban monotherapy compared with those of rivaroxaban plus antiplatelet therapy (combination therapy) in patients with atrial fibrillation and stable coronary artery disease. Objectives: This study sought to evaluate outcomes of rivaroxaban monotherapy in those patients across body mass index (BMI) categories. Methods: ). Efficacy (a composite of all-cause death, myocardial infarction, unstable angina requiring revascularization, stroke, or systemic embolism) and safety (major bleeding defined according to International Society on Thrombosis and Haemostasis criteria) were compared between rivaroxaban monotherapy and combination therapy across BMI categories. Results: 0.07), although monotherapy was superior to combination therapy for efficacy in normal weight (HR: 0.64; 95% CI: 0.44-0.95) and safety in overweight (HR: 0.25; 95% CI: 0.10-0.62), whereas a significant difference in the endpoints was not observed in the other BMI categories. Conclusions: Rivaroxaban monotherapy had a similar effect on prognosis across all BMI categories in patients with atrial fibrillation and stable coronary artery disease. (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease [AFIRE]; UMIN000016612, NCT02642419).
No takes yet. Share an insight, caveat, or question.
Ishii et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: